high pharmacologic doses (1-3 g/day) can cause hypotension, insulin resistance, and hepatotoxicity
Procedure Preheat spectrophotometer/microplate reader for 30 minutes, adjust the wavelength to 412 nm, set the counter to zero with distilled Preheat Reagent II in water bath for 30 minutes: 37 (mammal cell) or 25 (other species)
Some physicians use compounded options to "micro-dose," allowing a patient to take a dose smaller than the standard 0.25mg if their weight loss is occurring too rapidly
CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADERa landmark CVOT for Victoza 1 9,340 patients Key inclusion criteria: T2D, A1C 7.0% Age 50 years and established CVD OR Age 60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza was 1.78 mg Victoza significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years
These hormone changes can arise due to pregnancy, hormone replacement therapy (HRT), or hormonal contraceptives
In comparison, in the UK its younger Millennials (25-35) who use or have used GLP-1s the most
